Fertility Sparing Therapy for Patients With Stage IA G2 Endometrial Cancer

Launched by PEKING UNIVERSITY PEOPLE'S HOSPITAL · Jun 16, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating a type of treatment called fertility-sparing therapy for women with early-stage endometrial cancer, specifically those with a grade 2 tumor (which means it's moderately differentiated) that hasn't spread beyond the lining of the uterus. The goal is to find the best approach to treat this cancer while allowing women to preserve their ability to have children in the future. This is especially important as many women diagnosed with this type of cancer are younger and may want to start or grow their families.

To be eligible for this trial, participants need to be female, under 45 years old, and have a specific type of endometrial cancer that is limited to the endometrium (the inner lining of the uterus). They must also express a strong desire to keep their fertility and agree to participate in the study by signing an informed consent form. However, women with more advanced cancer or other serious health issues that could affect treatment won't be eligible. Since the trial is not yet recruiting, interested patients should stay tuned for when it opens and talk to their healthcare provider about their options.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Endometrioid adenocarcinoma G2, diagnosis by pathological.
• • The lesion is limited to the endometrium.
• • FIGO (2009) staging is IA.
• • Age less than 45.
• • Strongly request to preserve fertility.
• • Sign informed consent.
• Exclusion Criteria:
• • The tumor has invaded the muscle layer.
• • FIGO (2009) stage IB or higher.
• • Endometrioid adenocarcinoma G1, G3, or non-endometrioid cancer
• • There are malignant tumors in other systems.
• • Have contraindications for conservative treatment or drug use.
• • Have been judged by the researcher to be unsuitable for childbearing.